For COVID-19 vaccine updates, please review our information guide and sign up for Connect. Continue your routine care with us by scheduling an in-person appointment or Video Visit.

Warning message

The subscription service is currently unavailable. Please try again later.


Alternatives to Aggressive Therapy in Mantle Cell Lymphoma

Thursday, February 4, 2016

Peter Martin, M.D., assistant professor of Medicine in the Division of Hematology/Oncology, talks to Targeted Oncology about the evolving paradigm of treatment for mantle cell lymphoma. Martin says the evolution of the paradigm currently includes Bruton's tyrosine kinase inhibitor, phosphoinositide 3-kinase inhibitor, immunomodulatory treatments, and immunotherapies.

Martin says all the drugs mentioned have shown varying degrees of activity in mantle cell lymphoma, especially in the frontline setting. For patients with mantle cell lymphoma who are not amenable to particularly aggressive therapies, these treatments may provide alternative options.